Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Non-oral delivery systems in headache therapy

Focus on intranasal delivery

  • 17 Accesses

  • 3 Citations

Abstract

For many patients with migraine, and almost all patients with cluster headache, non-oral formulations of antimigraine drugs are required to achieve successful headache relief. Various non-oral options for drug delivery of antimigraine agents have been introduced — subcutaneous formulations, suppositories, inhaled formulations, and intranasal sprays.

Within the last decade, serotonin 5-HT1B/D receptor agonists (triptans) have become the drugs of first choice for the acute treatment of both migraine and cluster headache, and are available in various formulations. Despite this large variety, most patients still prefer oral medication over the available non-oral formulations, mainly because of the specific adverse events of non-oral formulations or their particular mode of administration.

The development of zolmitriptan intranasal spray, with a favourable pharmacokinetic and tolerability profile compared with existing oral formulations, may change patient preference towards intranasal administration. This article summarizes advantages and disadvantages of the available non-oral formulations used for the treatment of headache.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III
Table IV

Notes

  1. 1.

    The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. 1

    Dahlöf CGH. Characteristics of different routes of administration. In: Olesen J, Ferrari M, Humphrey PPA, editors. Frontiers in headache research: the triptans: novel drugs for migraine. Oxford: Oxford University Press, 2001: 80–90

  2. 2

    Volans GN. The absorption of effervesent aspirin in migraine. BMJ 1974; 4: 265–8

  3. 3

    Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867–71

  4. 4

    Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975; 2: 75–63

  5. 5

    Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4: 107–11

  6. 6

    Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984; 17: 67–75

  7. 7

    MacGregor EA, Wilkinson M, Bancroft K. Domperidone plus paracetamol in the treatment of migraine. Cephalalgia 1993; 13: 124–7

  8. 8

    Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurol 2002; 1: 251–7

  9. 9

    Dahlöf C. Integrating the triptans into clinical practice. Curr Opin Neurol 2002; 15: 317–22

  10. 10

    Eulenberg A. Subcutane injectionen von ergotamin (Tantret): ergotamin citricum solutum (Gehe). Dtsch Med Wochenschr 1883; 9: 637–9

  11. 11

    Dahlöf C, Goadsby P. Ergots: therapy. In: Diener HC, editor. Drug treatment of migraine and other headaches. Basel: Karger, 2000, 197–205

  12. 12

    Diener HC, Limmroth V. Advances in the pharmacological treatment of migraine. Expert Opin Investig Drugs 2001; 10: 1831–45

  13. 13

    Charlesworth B, Dowson A, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. CNS Drugs 2003; 17(9): 653–67

  14. 14

    Lennox WG. Ergonovine versus ergotamine as a terminator of migraine headaches. Am J Med Sci 1938; 195: 458–68

  15. 15

    Heyck H, Krayenbühl H. Der Kopfschmerz. Stuttgart: Thieme-Verlag, 1958

  16. 16

    Limmroth V, May A, Diener HC. Parenteral acetylsalicylic acid and ergot derivatives in migraine attacks. Eur Neurol 1999; 44: 81–93

  17. 17

    Stoll A, Hofmann A. Partialsynthese von Alkaloiden vom Typus des Ergobasins (6. Mitteilung über Mutterkorn-alkaloide). Helv Chim Acta 1943; 26: 944–50

  18. 18

    Silberstein SD. The pharmacology of ergotamine and dihydroergotamine mesilate. Headache 1997; 37Suppl. 1: S15–25

  19. 19

    Lipton RB. Ergotamine tartrate and dihydroergotamine mesilate mesylate: safety profiles. Headache 1997; 37Suppl. 1: S33–41

  20. 20

    Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine mesilate vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996; 53: 180–4

  21. 21

    Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6: 99–104

  22. 22

    Visser WH, Ferrari MD, Bayliss EM, et al. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group. Cephalalgia 1992; 12(5): 308–13

  23. 23

    Mathew NT, Dexter J, Couch J, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol 1992; 49(12): 1271–6

  24. 24

    Dahlöf C. Sumatriptan: pharmacological basis and clinical results. Curr Med Res Opin 2001; 17Suppl. 1: 35–45

  25. 25

    Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4

  26. 26

    Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45Suppl. 7: S5–9

  27. 27

    Yates R, Sorensen J, Bergstrom M, et al. Distribution and pharmacokinetics of zolmitriptan following administration by nasal spray [abstract]. Cephalalgia 2001; 21: 417

  28. 28

    Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharm 2002; 42: 1237–43

  29. 29

    Nairn K, Kemp JV, Dane AL, et al. Evaluation of the effect of xylometazoline on the absorption of zolmitriptan nasal spray. Clin Drug Invest 2002; 22(10): 703–7

  30. 30

    Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17(6): 431–47

  31. 31

    Dowson A, Charlesworth B. Review of zolmitriptan and its clinical applications in migraine. Expert Opin Pharmacother 2002; 3(7): 993–1005

  32. 32

    Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetic and efficacy. Drugs 2000; 60(6): 1259–87

  33. 33

    Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician’s view. Cephalalgia 2000; 20Suppl. 2: 14–24

  34. 34

    Humbert H, Cabiac MD, Cubray C, et al. Human pharmacokinetics of dihydroergotamine mesilate administered by nasal spray. Clin Pharmacol Ther 1996; 60: 265–75

  35. 35

    Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998; 55: 889–922

  36. 36

    Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(lB/lD) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358(9294): 1668–75

  37. 37

    Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39Suppl. 2: S20–6

  38. 38

    Rapoport AM, Sheftell FD. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 1997; 7: 37–46

  39. 39

    Dahlöf C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999; 19: 769–78

  40. 40

    Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994; 241: 463–9

  41. 41

    Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systemic review based on the number needed to treat. Cephalalgia 1998; 18: 532–8

  42. 42

    Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225–30

  43. 43

    Dahlöf CG, Boes-Hansen S, Cederberg CG, et al. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998; 18: 278–82

  44. 44

    Boureau F, Kappos L, Schoenen J, et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine mesilate nasal spray in the acute treatment of migraine. Int J Clin Pract 2000; 54: 281–6

  45. 45

    Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine mesilate nasal spray in the acute treatment of migraine. Neurology 1996; 47: 361–5

  46. 46

    Tulunay FC, Karan O, Aydin N, et al. Dihydroergotamine nasal spray during migraine attacks: a double blind crossover study with placebo. Cephalalgia 1987; 7: 131–3

  47. 47

    Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994; 44: 447–53

  48. 48

    Mathew N. Dosing and administration of ergotamine tartrate and dihydroergotamine mesilate. Headache 1997; 37Suppl. 1: S26–32

  49. 49

    Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695–9

  50. 50

    Bertin L, Brion N, Farkkila M, et al. A dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Int J Clin Pract 1999; 53(8): 593–8

  51. 51

    Tepper SJ, Cochran A, Hobbs S, et al., on behalf of the S2B351 Study Group. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 52: 31–5

  52. 52

    Pfaffenrath V, Salonen R. Clinical efficacy and tolerability of sumatriptan suppository in the acute treatment of migraine: a review of data from clinical trials [abstract]. Eur J Neurol 1998; 5Suppl. 3: S49

  53. 53

    Crooks J, Stephen SA, Brass W. Clinical trial of inhaled ergotamine tartrate in migraine. BMJ 1964; I: 221–4

  54. 54

    MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 2003; 43: 19–26

  55. 55

    Data on file. Harlow: GlaxoSmithKline, 2002

  56. 56

    Bigal ME, Sheftell F, Rapoport AM, et al. Triptan use in a migraineur population: determinants of preference [abstract S22.004]. Neurology 2003; 60Suppl. 1: A170

  57. 57

    Dowson A, Charlesworth BC, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003; 17(11): 839–51

  58. 58

    Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8:Suppl. 7: 1–96

  59. 59

    Dahlöf C. Clinical applications of new therapeutic deliveries in migraine. Neurology 2003; 61(8 Suppl. 4): S31–4

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Correspondence to Dr Volker Limmroth.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Limmroth, V., Dowson, A.J., Diener, H. et al. Non-oral delivery systems in headache therapy. Am J Drug Deliv 2, 59–68 (2004). https://doi.org/10.2165/00137696-200402010-00004

Download citation

Keywords

  • Migraine
  • Sumatriptan
  • Cluster Headache
  • Nasal Spray
  • Zolmitriptan